Seres Therapeutics (MCRB) Projected to Post Quarterly Earnings on Wednesday

Seres Therapeutics (NASDAQ:MCRB) is projected to announce its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect Seres Therapeutics to post earnings of ($1.0050) per share and revenue of $6.35 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of ($2.18) by $2.65. The company had revenue of $0.74 million for the quarter, compared to analysts’ expectations of $0.18 million. On average, analysts expect Seres Therapeutics to post ($6.33) EPS for the current fiscal year and ($2.06) EPS for the next fiscal year.

Seres Therapeutics Trading Down 9.1%

MCRB stock opened at $1.80 on Wednesday. Seres Therapeutics has a 12-month low of $1.70 and a 12-month high of $29.98. The company has a 50 day moving average of $3.78 and a two-hundred day moving average of $7.40.

Wall Street Analyst Weigh In

MCRB has been the topic of several research analyst reports. Weiss Ratings cut shares of Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 18th. Wall Street Zen upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $17.00.

About Seres Therapeutics

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.